Psychiatric Genomics, inc
Related Experiment Video
Updated: Sep 30, 2026

A Pipeline using Bilateral In Utero Electroporation to Interrogate Genetic Influences on Rodent Behavior
Published on: May 21, 2020
1Psychiatric Genomics, Inc., 19 Firstfield Rd, Gaithersburg, MD 20878, USA. mpalfreyman@psygenomics.com
Abstract:
Mental illness affects millions of patients and has been shown to have multiple genetic components. The interaction of environmental factors, such as stress, with the expression of genetic susceptibilities has hampered the development of novel and effective drug treatments. A new approach is described that can discover novel classes of drugs for the treatment of the underlying causes of these diseases rather than their symptoms. This approach screens drug candidates according to their ability to alter the expression of multiple genes in a multiparameter high-throughput screening assay (MPHTS SM) that does not require a prori knowledge of the targets of screening assays. Clinical development of drug candidates will be pursued through partnerships with pharmaceutical companies and/or large biotechnology companies.
Related Concept Videos
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
